Recent Trends of Infliximab Treatment for Crohn's Disease.
10.5223/pghn.2012.15.1.19
- Author:
Mi Jin KIM
1
;
Yon Ho CHOE
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. i101016@skku.edu
- Publication Type:Review
- Keywords:
Crohn's disease;
Infliximab
- MeSH:
Abscess;
Antibodies, Monoclonal;
Constriction, Pathologic;
Crohn Disease;
Fistula;
Gastrointestinal Tract;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Pediatric Gastroenterology, Hepatology & Nutrition
2012;15(1):19-22
- CountryRepublic of Korea
- Language:English
-
Abstract:
Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract and characterized by relapsing and remitting episodes, with progression over time to complications of stricture, fistulas, or abscesses. The etiology is unknown, although the common opinion is that the disease arises from a disordered immune response to the gut contents in genetically predisposed individuals. Infliximab is a mouse-human chimeric antibody against tumor necrosis factor alpha, and has proven to be effective in active Crohn's disease for both induction and maintenance therapy. Despite the growing experience with infliximab in Crohn's disease, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of infliximab in Crohn's disease and to discuss the yet-unsolved issues.
